Phaseline

Targets › TMSB4X

TMSB4X (Thymosin beta-4): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Cardiovascular; next expected readout Feb 2027.

Plays an important role in the organization of the cytoskeleton. Binds to and sequesters actin monomers (G actin) and therefore inhibits actin polymerization..; FUNCTION: [Hemoregulatory peptide AcSDKP]: Potent inhibitor of bone marrow derived stem cell differentiation. (UniProt, P62328)

Open in Phaseline: the race on TMSB4X, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Hudson BiotechTB-500
Thymosin beta 4 17-23 fragment
TMSB4XPhase 1Atherosclerotic Cardiovascular DiseasesFeb 2027

Conditions

Atherosclerotic Cardiovascular Diseases (1)

Modalities

small molecule (1)

Companies

Hudson Biotech (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.